MTRAC issued an updated Commissioning Support guidance in December 2014. The review covers fluticasone / formoterol inhaler.
The fluticasone / formoterol inhaler (Flutiform®) summary advises that this combination inhaled corticosteroid / long-acting beta agonist inhaler is suitable for prescribing in primary care for the treatment of asthma. It is noted that in two 12-week RCTs, flutiform was found to be non-inferior to a fluticasone / salmeterol inhaler (Seretide®), and a budesonide / formoterol inhaler (Symbicort®) respectively for the primary outcome of change in pre-dose FEV1 from baseline.
Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.